Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + zotiraciclib
- Development stage
- Unknown
- Lead developer
- Cothera Bioscience
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Temozolomide + zotiraciclib is a combination therapy being investigated for the treatment of recurrent high-grade gliomas. Temozolomide is an alkylating agent commonly used to treat brain tumors, while zotiraciclib is a multi-kinase inhibitor that acts primarily as a CDK9 inhibitor. This combination works by depleting short-lived survival proteins such as c-MYC and MCL-1 which are overexpressed in glioblastoma, while also causing DNA damage through temozolomide's alkylating properties. Zotiraciclib penetrates the blood-brain barrier, making it particularly suitable for brain tumor treatment. The combination has shown promising results in clinical trials, particularly in patients with IDH1-mutated gliomas.
- Other names
- ZTR
02
Targets
CDK9 (Cyclin-dependent kinase 9)DNA
Beyond the preview
Go deeper on temozolomide + zotiraciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + zotiraciclib.